Dr. Reddy's announces first-to-market launch of Carboprost Tromethamine Injection USP

image credit- istock.com

Dr. Reddy’s Laboratories Ltd., along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial, a therapeutic equivalent generic version of Hemabate® injection,  250 mcg/mL, approved by the U.S. Food and Drug Administration (USFDA).  

“We are pleased to be first-to-market with this product that has been designated as a Competitive Generic Therapy (CGT) by the FDA,” says Marc Kikuchi, Chief Executive Officer, North America Generics,

Dr. Reddy’s Laboratories. “With a CGT designation, we have 180-day CGT exclusivity to market this product.” 

The Hemabate® injection, 250 mcg/mL brand had U.S. sales of approximately $55 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health.